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Background: The St Gallen surrogate molecular subtype definitions classify the oestrogen (ER) positive breast
cancer into the luminal A and luminal B subtypes according to proliferation rate and/or expression of human
epidermal growth factor receptor 2 (HER2) with differences in prognosis and chemo-responsiveness. Primary
tumours and lymph node metastases might represent different malignant clones, but in the clinical setting only the
biomarker profile of the primary tumour is used for selection of adjuvant systemic treatment. The present study
aimed to classify primary breast tumours and matched lymph node metastases into luminal A, luminal B,
HER2-positive and triple-negative subtypes and compare the distributions.
Methods: Eighty-five patients with available tumour tissue from both locations were classified. The distribution of
molecular subtypes in primary tumours and corresponding lymph node metastases were compared, and related to
5-year distant disease-free survival (DDFS).
Results: The St Gallen molecular subtypes were discordant between primary tumours and matched lymph node
metastases in 11% of the patients (p = 0.06). The luminal A subtype in the primary tumour shifted to a subtype with
a worse prognostic profile in the lymph node metastases in 7 of 45 cases (16%) whereas no shift in the opposite
direction was observed (0/38) (p = 0.02). All subtypes had an increased hazard for developing distant metastasis
during the first 5 years after diagnosis in both primary breast tumours and matched lymph node metastases,
compared with the luminal A subtype.
Conclusion: The classification according to the St Gallen molecular subtypes in primary tumours and matched
lymph node metastases, implicates a shift to a more aggressive subtype in synchronous lymph node metastases
compared to the primary breast tumour. The selection of systemic adjuvant therapy might benefit from taking the
molecular subtypes in the metastatic node into account.
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Breast cancer is a heterogeneous disease with variations in
the biological profile and subsequent clinical prognosis.
Prognostic information for the individual patient is based
on the analysis of biological markers in the primary
tumour including oestrogen receptor (ER), progesterone
receptor (PR), human epidermal growth factor receptor 2
(HER2) and Ki67, together with age, tumour size, histo-
logical grade and lymph node engagement [1]. However,
the clinical outcome varies despite identical biomarker
profiles and stages: 20% of patients with node-negative
breast cancer disease will have a recurrence and more
than 30% of patients with lymph node metastases will
remain disease-free [2,3]. Accordingly, a more precise
prognostic tool is needed to identify patients who would
benefit from adjuvant therapy as well as patients for which
adjuvant therapy can be safely omitted.
Microarray-based gene expression studies [4,5] and sub-
sequent immunohistochemical studies [6-9] have shown
that further prognostic and predictive information can be
gained by combining biological markers in the primary
tumour rather than assessing them individually [6-8]. In
2011, the St Gallen International Breast Cancer Confer-
ence suggested a surrogate definition of intrinsic subtypes
of breast cancer: luminal A (ER + and/or PR+, Ki67 low
and HER2-), luminal B (ER + and/or PR+, Ki67 high and/
or HER2+), HER2-positive (ER-, PR- and HER2+) and
triple negative (ER-, PR-, HER2-) [10]. The classification
has highlighted the heterogeneity of ER positive tumours
in terms of prognosis. The luminal A subtype has a
favourable prognosis compared to the luminal B subtype
and the systemic therapy advocated for the patients with
luminal A tumours is generally restricted to endocrine
therapy. The luminal B subtype has a high proliferation
rate and/or a high histological grade and systemic treat-
ment with chemotherapy followed by endocrine therapy is
recommended [10,11].
Selection of adjuvant systemic therapy is based on
analysis of routinely used biomarkers in the primary
tumour assuming that tumour biological markers are
stable throughout tumour progression. Studies of paired
samples of primary tumours and their metastatic lymph
nodes and/or distant metastases suggest that tumour
receptor status may be discordant in a fraction of patients
[12-14] with influence on prognosis [13,15] proposing a
more aggressive phenotype in the metastases in patients
with disseminated disease. In a recent study, change of
therapy according to biomarker expression in the meta-
static site improved prognosis in the affected patients [16],
stressing the clinical benefit of a biopsy of the recurrence
as well as tailoring of therapy according to the biomarker
profile in the metastatic location.
Analysis of individual biomarker expression (ER, PR,
Ki67 and HER2) in primary breast cancer and synchronouslymph node metastases has shown that there is a small
fraction of discordant cases but the prognostic implication
for the individual patient is not settled [14,17-19]. Previous
studies of biomarkers in synchronous lymph node metas-
tases and asynchronous metastatic locations have focused
on individual markers and lack information on the distri-
bution of the St Gallen molecular subtypes. The present
study aimed to investigate whether classification into lu-
minal A, luminal B, HER2-positive and triple-negative
subtypes provides information beyond that of the individ-
ual analyses of ER, PR, HER2 and Ki67 when comparing
the inherence between the primary tumour and matched
lymph node metastases in terms of distribution and prog-
nosis. The St Gallen Guidelines from 2011 highlights the
heterogeneity of ER positive disease with clear implica-
tions for selection of systemic adjuvant therapy and the
present study addresses if analyses of the distribution of
the intrinsic subtypes in synchronous metastatic lymph
nodes can have therapeutic implications in addition to
analyses of the primary tumour.
Results
St Gallen molecular subtype classification in the primary
tumour and corresponding lymph node metastases
Patient and primary tumour characteristics are summarised
in Table 1. In 9/85 cases (11%) the molecular subtype
classification was discordant between the primary tumour
and the lymph node metastasis (Table 2). The asymmetric
pattern of the observed discordances indicates that the
shift is non-random (p = 0.06, McNemar-Bowker test of
symmetry). Moreover, 16% (7/45) of the cases which were
luminal A in the primary tumour shifted to a subtype with
a worse prognosis according to the lymph node metasta-
ses, whereas not a single shift in the opposite direction
was observed (0/38). This asymmetry, when comparing lu-
minal A vs. non-luminal A in the primary tumour and the
lymph node, was significant (p = 0.02, McNemar-Bowker
test of symmetry). The remaining two cases shifted from
HER2-positive and triple negative in the primary tumour
to luminal B subtype and HER2-positive in the lymph
node (Table 2).
Survival analysis
Three degree of freedom log rank tests revealed significant
differences in DDFS and OS between the subtypes for
both primary tumors (p = 0.002 and p < 0.001, respect-
ively) and lymph node metastases (p = 0.003 and p < 0.001,
respectively) with the HER2-positive and triple-negative
subtype associated with the shortest survival time (Figures 1
and 2). The difference in DDFS between the subtypes of
both primary breast tumour and paired lymph node was
further evaluated with Cox proportional hazards model.
For both the primary breast tumour and paired lymph
node all subgroups had an increased hazard of developing
Table 2 Distribution of St Gallen molecular subgroups in prim
M
Luminal
Molecular phenotype in breast tumour luminal A 38 (85)
luminal B 0
HER2-positive 0
N (%) Triple negative 0
Total 38
p = 0.06 McNemar-Bowker test of symmetry for all subclasses.
p = 0.02 McNemar-Bowker test of symmetry for Luminal A subclass versus non-Lumi
N = number of patients, percentages are given within parenthesis.
Table 1 Clinicopathological data of the included patients
Characteristics Number of patients (%)
All patients 85 (100)
Age Median (range) 64 (26–76)
HER2 Positive 17 (20)
Negative 68 (80)
Ki67 ≤ 20% 54 (74)
> 20% 19 (26)
ER status Positive 62 (73)
Negative 23 (27)
Pr status Positive 41 (48)
Negative 44 (52)
Histology Ductal 67 (81)
Lobular 10 (12)
Ductal + Lobular 4 (5)
Other 2 (2)
Missing 2
Tumor size ≤ 20% 25 (29)
> 20% 60 (71)




Nodal status N1 22 (26)
N2-3 25 (29)
N4+ 38 (45)
Events1 Yes 25 (29)
No 60 (71)
Abbreviations: ER oestrogen receptor, PR progesteron receptor, HER2 human
epidermal growth factor receptor 2, Grade Nottingham histological grade.
1Events: recurrence and/or death in breast cancer disease.
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compared with the luminal A subclass (Table 3). In
multivariable analysis, adjusting for calendar-period,
age at time of diagnosis and study regime (postmeno-
pausal versus premenopausal cohort), results were simi-
lar although not statistically significant for all subtypes
(Table 3).
Patients switching from luminal A in the primary
tumour to non-luminal A in the lymph node metastases
(n = 7) had no significant change in prognosis compared
to the stable luminal A subgroup (n = 38) or to the stable
non-luminal A subgroup (n = 40) in terms of DDFS and
OS (data not shown). However, the number of patients
shifting from luminal A to non-luminal A are few, and no
definitive conclusions can be drawn from this study. One
patient shifting from triple-negative in the primary tumour
to HER2-positive subtype in the lymph node metastases
had distant metastases and died within one year, whereas
the patient shifting from HER2-positive subtype to a
luminal B subtype was without any event at 5 years
follow-up.Discussion
Combining biological tumour markers into surrogate
molecular subtypes has been shown to add prognostic
information [6-8,10,11] which may be of importance for
recommendation of systemic therapy. Unlike the analyses
of individual biomarkers in the present cohort of patients
[17] which showed high concordance between primary tu-
mours and corresponding lymph node metastases, the
molecular subtypes identify a subgroup of patients with
ER positive disease as luminal B, with a worse prognosis,
who may benefit from adjuvant chemotherapy alongside
endocrine treatment [10,14,20]. We found the prognosis
according to the molecular subtypes to be superior for the
luminal A subtype in primary tumours as well as in syn-
chronous lymph node metastases. A subset of patients
shifting from a luminal A subtype in the primary tumour
to a non-luminal A subtype in the metastatic lymph nodeary breast tumours and matched lymph node metastases
olecular phenotype in lymph node metastases Total
N
A Luminal B HER2-positive Triple negative
5 (11) 0 2 (4) 45 (100)
17 (100) 0 0 17 (100)
1 (9) 10 (91) 0 11 (100)
0 1 (8) 11 (92) 12 (100)
23 11 13 85 (100)
nal A subclasses.
A Distant disease-free survival (DDFS) by St Gallen molecular subtypes in primary tumours
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Figure 1 Distant disease-free survival (DDFS) and overall survival (OS) by St Gallen molecular subtypes in primary tumours. A. Distant
disease-free survival (DDFS) by St Gallen molecular subtypes in primary tumours. B. Overall survival (OS) by St Gallen molecular subtypes in
primary tumours.
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would have improved prognosis.
The present cohort, with patients included in two pro-
spective trials of adjuvant tamoxifen, was initiated decades
ago. The distribution of molecular subtypes in the primary
tumour is, however, similar to today’s distribution with
13% of the tumours being HER2 overexpressed and more
than 50% having a luminal A phenotype [11]. The finding
of a shift in molecular subtype from the primary tumour
to the metastases is thus not necessarily influenced by the
draw-backs of including a cohort not offered modern
treatment. The prognosis, however, is dependent not only
on the phenotype of the tumour and the metastases, butalso on the calendar-period including the treatment
offered at that time. Survival analyses were adjusted also
for calendar-period with similar results. The study only in-
cludes 85 patients and is not powered to find any differ-
ence in presentation of four molecular subtypes in the
primary tumour versus metastases. Hence, the shift of a
molecular subtype towards a more aggressive subtype in
the metastatic lymph node is a hypothesis-generating find-
ing in line with recent publications [21]. In the recently
published study from our group [22] comparison of mo-
lecular subtypes in primary tumour and synchronous
lymph node metastases also revealed a shift in individual
patients. The shift was observed from luminal A to non-
A Distant disease-free survival (DDFS) by St Gallen molecular subtypes in matched lymph node 
metastases
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Figure 2 Distant disease-free survival (DDFS) and overall survival (OS) by St Gallen molecular subtypes in matched lymph node
metastases. A. Distant disease-free survival (DDFS) by St Gallen molecular subtypes in matched lymph node metastases. B. Overall survival (OS)
by St Gallen molecular subtypes in matched lymph node metastases.
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shift, from non-luminal A to luminal A in the metastatic
node. In the present study, only shifts to a molecular sub-
type with worse prognosis were observed. The number of
patients in the present study cohort is limited (N = 85)
and the inclusion was restricted to patients with stage II
breast cancer whom all received adjuvant treatment with
tamoxifen irrespective of expression of ER as opposed to
the patients in the more recent study [22] which consti-
tutes an unselected cohort where patients were offered ad-
juvant treatment according to modern guidelines. The
analyses of HER2 also differ between the studies, where
assessment according to immunohistochemistry (IHC)
(present) or silver in situ hybridization (SISH) [22] could
affect the results. Interestingly, shifts are observed inindividual patients in both patient cohorts according to
molecular subtypes, proposing a molecular event in the
metastatic niche during tumour cell progression with
influence on prognosis.
Tissue analysis
The individual biomarker discordance between primary
tumours and metastases may reflect tumour progression,
although test artefacts have also been proposed. For HER2
analysis, a recent meta-analysis including 26 primary pub-
lications has suggested that limitations of test reproduci-
bility are less likely to explain the discordance in HER2
status found between primary tumours and metastatic
sites [23]. The authors found a low HER2 discordant pro-
portion for synchronous lymph node metastases compared
Table 3 Cox proportional hazards regression analysis of 5-year distant disease-free survival according to St Gallen
Molecular subtypes with luminal A as reference group
A. Univariable analysis
Primary tumour Lymph node metastases
Frequency
N (%)
HR (95% CI) p-value Frequency
N (%)
HR (95% CI) p-value
luminal A 45 (53) 1.0 38 (45) 1.0
luminal B 17 (20) 2.8 (0.94-8.4) 0.064 23 (27) 3.1(1.0-9.5) 0.048
HER2-positive 11 (13) 4.5 (1.4-14) 0.011 11 (13) 7.3 (2.2-24) 0.001
Triple negative 12 (14) 5.9 (2.1-17) 0.001 13 (15) 4.6 (1.4-15) 0.011
B. Multivariable analysis
Primary tumour1 Lymph node metastases1
Frequency
N (%)
HR (95% CI) p-value Frequency
N (%)
HR (95% CI) p-value
luminal A 45 (53) 1.0 38 (45) 1.0
luminal B 17 (20) 2.9 (0.96-8.8) 0.059 23 (27) 2.9 (0.92-9.0) 0.070
HER2-positive 11 (13) 3.1 (0.94-10) 0.063 11 (13) 4.8 (1.3-17) 0.016
Triple negative 12 (14) 4.6 (1.6-13) 0.006 13 (15) 3.9 (1.2-13) 0.029
1Adjusted for calendar-period (year at time of operation), age (years) and study regime (postmenopausal versus premenopausal study).
Abbreviations: HER2 human epidermal growth factor receptor 2, HR hazard ratio, CI confidence interval, N number of patients, percentages are given
within parenthesis.
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tumour progression plays a major role. In the present
study, biopsies were obtained by a manual arrayer from
lymph nodes corresponding to the primary tumour and
further processed as described previously for analyses of
HER2 and Ki67. The method has limitations because a
small area of one of the metastatic lymph nodes is
examined. Sampling may therefore contribute to bias in
representative areas of evaluation.
In the present study, 8/85 tumours were classified as
HER2 2+ according to IHC analyses. In a national survey
performed by our group, 12% of HER2 2+ tumours were
amplified according to fluorescence in situ hybridization
FISH [24] and in another study [25] the concordance
was up to 24%. This would result in 1–2 patients of
HER2 2+ tumours as amplified in the present cohort,
thus patients with HER2 2+ tumours were included as
HER2-negative.
Cut-off values
The previously defined cut-off values for biomarker ex-
pression are based on accepted guidelines [26,27] in which
Ki67 is the least studied with few validated guidelines
available. In the present study, representative areas for the
TMAs were examined to identify cancerous regions within
a tissue sample. Areas in the region with increased num-
ber of Ki67 positive cells, hot spots, were identified and
the number of positive cells was assessed and index calcu-
lated. The present study used a predefined 20% cut-off
point based on the population sectioning, distinguishingthe one third of the patients in the population with
the highest proliferation from the remaining two
thirds [28,29]. The prognostic value of Ki67 has been
investigated in several recent publications [6,28,30] but
the assessment of the cut-off value of Ki67 is not settled
and the reliability of the measures varies in different geo-
graphic settings [10]. The cut-off value of ER responsive-
ness in clinical practice is traditionally 10%. This cut-point
was chosen also in the present study, although there is
support for a lower cut-off value of 1% for endocrine treat-
ment and thus the detection of any ER positive cell in the
tumour will define it as an ER responsive tumour [10].
ASCO/PAP guidelines support the 1% cut-off [27] but the
guidelines are questioned in a recent study [31].
The results in this study indicate tumour instability in
clinically used markers in combination classified according
to the St Gallen molecular subtypes between primary
breast cancer and synchronous matched lymph node me-
tastases. Furthermore, the survival analyses show that the
St. Gallen molecular subtypes have similar prognostic im-
plications in primary tumours and matched lymph node
metastases. Node status is still a powerful prognostic fac-
tor in primary breast cancer despite advanced molecular
techniques. A shift in molecular characteristics to a more
aggressive phenotype in synchronous nodal metastases
compared to the primary tumour suggests that tumour
progression occurs already at time of diagnosis in a frac-
tion of breast cancer patients with node positive disease.
The selection of more aggressive cell clones in lymph
node metastases can be an additional explanation to the
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primary breast cancer, besides a more advanced stage of
the disease.
Conclusions
The present study shows that a proportion of the ER
positive group of patients with a luminal A subtype in
the primary tumour gain proliferation and/or HER2
amplification in the metastatic lymph node and switch
inherence to a subtype with impaired DDFS. Data from
patients with metastatic breast cancer suggests that se-
lection of systemic therapy should be guided by bio-
marker analysis in the metastases [13,32]. If adjuvant
treatment selection is to be based also on the molecular
subtype in synchronous lymph node metastases, chemo-
therapy would have been advocated for patients shifting
from luminal A to a non-luminal A subtype, alongside
endocrine treatment. Biomarker analysis in matched
lymph node metastases could easily be implemented in
clinical practice if it would be of value for adjuvant
treatment selection. Future studies including larger co-
horts of patients are necessary in order to evaluate the re-




The study is based on a cohort of patients previously
selected from two prospective randomised clinical tri-
als to investigate the compatibility of different labora-
tory methods for the evaluation of hormonal receptor
status [33]. The original studies included patients from
the South–Swedish Health Care Region (hospitals in
Simrishamn, Ystad, Trelleborg, Malmö, Lund, Landskrona,
Hässleholm, Ängelholm, Kristianstad, Halmstad, Ljungby,
Växjö, Karlskrona and Karslhamn) during 1985–1994
irrespective of hormonal receptor status and with stage
II unifocal, radically operated early breast cancer with-
out distant metastases. In the postmenopausal study,
the patients were allocated to 2 years (n = 496) versus
5 years (n = 469) of adjuvant tamoxifen treatment [34].
For premenopausal patients, identical inclusion- and
exclusion criteria were used except for menopausal sta-
tus and patients were allocated to two years of tamoxifen
(n = 213) versus no adjuvant treatment (n = 214) [35]. No
other adjuvant therapy was allowed and less than 1% of
the premenopausal patients received polychemotherapy.
The original cohort of the quality-assurance study in-
cluded 425 patients treated with adjuvant tamoxifen for
two years, 297 of whom had lymph node metastases
(Figure 3). All the patients underwent surgical treat-
ment of the breast and axilla. Radiotherapy was given to
the breast in the case of breast-conserving surgery, and
locoregionally if lymph node metastases were present.Adjuvant systemic treatment was given as 2 years of
tamoxifen irrespective of hormone receptor status. The
patients had annual mammograms and physical investi-
gations for 5 years. For the patients who were classified
in the present study (n = 85), the median follow-up for
DDFS was 5.1 years for patients alive and without metas-
tases. The trial was approved by the Ethics committee at
Lund University (LU240-01) and informed consent was
obtained from all included patients.
The cohort of patients was recently re-examined for
differences in individual biomarker presence between the
primary tumour and the lymph node metastases [17]. In-
formation on clinical outcome as well as patient and
tumour characteristics was therefore already available. In
the present study, it was possible to classify 85 patients
from the original cohort into the four subtypes of luminal
A, luminal B, HER2-positive and triple negative according
to ER, PR, HER2 and Ki67. The immunohistochemical
staining of primary tumours and lymph node metastases
was performed at the same time. Patient and tumour char-
acteristics for these 85 patients are summarised in Table 1.
They reveal a cohort of patients with known metastases in
the axilla, so the fraction of events is, as expected, high
(25/85). This is also reflected by the high fraction of large
tumours (>20 mm: 71%).
Tissue microarrays
In the previous study [17], tissue microarrays from pri-
mary tumours and ipsilateral lymph node metastases
were constructed for analysis of Ki67 and HER2. Repre-
sentative areas of invasive breast cancer, embedded in
paraffin blocks, were marked. Two cores (0.6 mm) from
each tumour block of the primary tumour were
punched out and one biopsy specimen from the corre-
sponding lymph node metastases was obtained by a
manual arrayer (Beecher Instruments, Sun Prairie, WI,
USA) and positioned into a recipient paraffin array block.
Staining with haematoxylin and cytokeratin (AE1/AE3)
was carried out for a morphological overview and the
localization of cancer cells. One section per tissue speci-
men (primary tumour and lymph node metastases) and
biomarker was evaluated.
HER2 scoring was determined after staining with a
primary antibody (A0485, DAKO, Glostrup, Denmark)
using a standard protocol (HercepTest™) to quantify and
categorize tumours into four groups: 0: no staining in all
tumour cells, or membrane staining in fewer than 10%
of tumour cells; grade 1+: weak, not circumferential
staining in more than 10% of the tumour cells; grade 2+:
intermediate, circumferential staining in more than 10%
of the tumour cells; and grade 3+: intense and circumfer-
ential membrane staining in more than 10% of the tumour
cells. HER2 scoring was denoted as HER2-positive for all
3+ tumours and HER2-negative in 0, 1+ and 2+.
Primary tumour
N = 425
Lymph node metastases, 
N = 297 
ER analysis in primary 
tumour and corresponding 
lymph node assessed        
N = 262
PR analysis in primary 
tumour and corresponding 
lymph node assessed        
N = 257
Ki67 analysis in primary 
tumour and corresponding 
lymph node assessed        
N = 101
HER2 analysis in primary 
tumour and corresponding 
lymph node assessed        
N = 104
Available for assessment 
of molecular subgroup
by combining ER, PR, 
Ki67 and HER2 in 
primary tumor and 
corresponding lymph node 
N = 85
No lymph node metastasis
N = 128
Primary tumour         
Tissue available 
N = 425
Lymph node metastases 
Tissue available 
N = 273
TMA constructed for primary tumour, N = 425        
and lymph node metastasis, N = 273, for further 
analysis of Ki67 and HER2
Figure 3 Flow chart of study cohort. Abbreviations: ER = Oestrogen receptor, PR = Progesterone receptor, HER2 = Human epidermal growth
factor receptor 2, TMA = Tissue microarray.
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antibody MIB-1 (M7240, DAKO). Sections of 4 μm were
cut, mounted onto capillary microscope slides (DAKO),
dried overnight at room temperature followed by 1–2 h
at 60°C. The sections were deparaffinized in xylene and
rehydrated in a graded series of ethanol. Antigen re-
trieval was performed in a microwave oven, pH 9 buffer
(S2367, DAKO). Staining was performed using an auto-
matic immunostainer (TechMate™ 500 Plus, DAKO)
with an incubation time of 30 min at room tempera-
ture and with MIB-1 diluted 1:1000. DAKO Envision™
(DAKO,) was used as the visualization system. Diamino-
benzidene was used as the chromogen. The IHC staining
was examined by light microscopy by two independent
observers. A cut-off point of > 20% labelled nuclei was
used to demarcate high Ki67 [28,29].ER and PR were previously analyzed with IHC on
formalin-fixed, paraffin-embedded breast carcinoma on
whole slides, and were considered positive when more
than 10% of the nuclei were stained [33].Molecular subtype classification
The categorisation of molecular subtypes was constructed
according to the St Gallen International Breast Cancer
Conference 2011 [10]: luminal A (ER + and/or PR+, Ki67
low and HER2-), luminal B (ER + and/or PR+, Ki67 high
and/or HER2+), HER2-positive (ER-, PR- and HER2+) and
triple-negative type (ER-, PR- and HER2-). In 85 patients
of 297 with lymph node metastases, all markers were
known and the patients were possible to classify into the
four subtypes.
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The classifications of primary breast cancer tumours and
corresponding lymph node metastases by molecular sub-
types were compared using the exact McNemar-Bowker
test of symmetry. The null hypothesis of this test is that
the matrix formed by cross tabulation of the molecular
subtype variables is symmetric and the alternative that it
is not. Significant deviation from symmetry indicates a
non-random subtype shift from the primary tumour to
the lymph node metastases. The test is a generalisation
of the McNemar test to more than two categories. Distant
disease-free survival (DDFS) was the primary end-point
and included any distant relapse (lung, liver, bone, brain,
bowel) or breast cancer death as primary event and was
calculated from the day of operation until the first event
or the last review of the patient’s record. Overall survival
was the secondary endpoint and included deaths of any
cause. The molecular subtypes were related to clinical out-
come in terms of DDFS by Cox analysis with luminal A as
the reference group. Proportional hazards assumptions
were checked with Schoenfeld’s test and deviations from
proportionality were observed for the nominal molecular
subtype variables (3-df tests). To reduce this problem, the
follow-up was restricted to the first 5 years after diagnosis,
but also for this interval, the hazard ratios should be inter-
preted as time average effects because the effects level off
with time.
P-values less than 0.05 were considered significant.
The statistical software package Stata 12.1 (Stata Corp.
College Station, TX, USA) was used for all the statistical
calculations.
Abbreviations
ER: Oestrogen receptor; PR: Progesterone receptor; HER2: Human epidermal
growth factor receptor 2; NHG: Nottingham histological grade; DDFS: Distant
disease-free survival; OS: Overall survival; IHC: Immunohistochemistry;
ISH: in situ hybridization; HR: Hazard ratio; CI: Confidence interval.
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